<DOC>
	<DOCNO>NCT00100698</DOCNO>
	<brief_summary>This study investigate long-term , low-dose growth hormone administration HIV-infected patient reduce growth hormone ( GH ) secretion increase visceral adiposity . We hypothesize low-dose growth hormone reduce visceral fat . Secondary endpoint include measure insulin-like growth factor-1 ( IGF-1 ) , glucose homeostasis , lipid , blood pressure , bone density , cardiovascular risk safety parameter .</brief_summary>
	<brief_title>Physiologic Growth Hormone Effects HIV Lipodystrophy</brief_title>
	<detailed_description>This study investigate long-term , low-dose growth hormone administration HIV-infected patient reduce growth hormone ( GH ) secretion increase visceral adiposity . We hypothesize low-dose growth hormone reduce visceral fat preferentially subcutaneous fat , increase lean body mass . Secondary endpoint include measure IGF-1 , glucose homeostasis , lipid , blood pressure , bone density , cardiovascular risk safety parameter . Dosing growth hormone base patient ' IGF-1 level exceed 6mcg/kg/day .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Men woman age 1860 Previously diagnose HIV infection Stable antiviral regimen least 12 week prior enrollment Waisttohip ratio &gt; 0.90 men &gt; 0.85 woman Evidence least one follow recent change : *increased abdominal girth , *relative loss fat extremity , *relative loss fat face Simulated peak GH response arginine/GHRH le 7.5 mcg/dL Use Megace , antidiabetic agent , GH , anabolic agent , pharmacologic glucocorticoid ( prednisone &gt; 5 mg/day equivalent ) 3 month prior enrollment . Patients standard dose testosterone document hypogonadism allow enter protocol . Women take standard estrogen replacement therapy &gt; 3 month allow study . Diabetes mellitus Other severe chronic illness HgB &lt; 9.0 g/dL , creatinine &gt; 1.4 mg/dL , PSA &gt; 4 ng/mL Positive BHCG failure use appropriate birth control study . Acceptable method include oral contraceptive , depo provera combine progesteroneestrogen injection , transdermal contraceptive patch , IUD 's , barrier device ( condom , diaphragm ) , abstinence . Carpal tunnel syndrome Active malignancy history pituitary malignancy , history colon cancer prostate malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>HIV</keyword>
	<keyword>lipodystrophy</keyword>
	<keyword>growth hormone</keyword>
	<keyword>visceral fat</keyword>
	<keyword>IGF-I</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>